| felzartamab (MOR202) / Biogen |
NCT03952091: TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Completed | 3 | 289 | RoW | TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone | TJ Biopharma Co., Ltd. | Multiple Myeloma in Relapse, Refractory Multiple Myeloma | 06/24 | 06/24 | | |
|
TRANSCEND, NCT06685757: A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR) |
|
|
| Not yet recruiting | 3 | 120 | US | Felzartamab, MOR202, MOR03087, TJ202, HIB202, BIIB148, Placebo | HI-Bio, A Biogen Company, Biogen | Antibody-mediated Rejection | 12/26 | 06/27 | | |
2021-000545-40: Safety, Tolerability and Efficacy of the Therapeutic Antibody Felzartamab in Rejection Late After Kidney Transplantation Sicherheit, Verträglichkeit und Wirksamkeit des therapeutischen Antikörpers Felzartamab bei Abstoßung spät nach Nierentransplantation |
|
|
| Ongoing | 2 | 20 | Europe | Felzartamab, Lyophilisate for solution for infusion | Medical University of Vienna, MorphoSys AG | Late active or chronic active antibody-mediated rejection, Immunological rejection of a kidney transplant late after transplantation, Body processes [G] - Immune system processes [G12] | | | | |
2021-000835-30: MOR202 for refractory MN Impiego di Felzartamab in pazienti con nefropatia membranosa resistenti alla terapia con anticorpi anti-CD20 |
|
|
| Not yet recruiting | 2 | 10 | Europe | MOR202, [MOR202], Lyophilisate for solution for infusion | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, MorphoSys AG, Istituto di Ricerche Farmacologiche Mario Negri IRCCS | Membranous Nephropathy who Failed Anti-CD20 Target Therapy. Nefropatia membranosa resistente alla terapia con anti-CD20., Membranous Nephropathy who Failed Anti-CD20 Target Therapy. Nefropatia membranosa resistente alla terapia con anti-CD20., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
NCT03860038: TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 2 | 113 | RoW | TJ202 and Dexamethasone | TJ Biopharma Co., Ltd. | Multiple Myeloma in Relapse, Refractory Multiple Myeloma | 01/23 | 12/24 | | |
| Completed | 2 | 54 | Europe, Japan, US, RoW | Felzartamab, MOR202, Placebo | HI-Bio | Immunoglobulin A (IgA) Nephropathy | 02/23 | 05/24 | | |
| Completed | 2 | 24 | Europe, RoW | MOR202 | HI-Bio | Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive | 12/23 | 12/23 | | |
| Completed | 2 | 22 | Europe | Felzartamab, MOR202, CD38 monoclonal antibody, Placebo, 0.9% Saline | Farsad Eskandary, Charite University, Berlin, Germany, University of Alberta, HI-Bio | Antibody-mediated Rejection | 03/24 | 03/24 | | |
| Active, not recruiting | 2 | 10 | Europe | MOR202, FELZARTAMAB | Mario Negri Institute for Pharmacological Research, MorphoSys AG | Membranous Nephropathy | 02/25 | 02/25 | | |
| Completed | 1 | 24 | RoW | T, R | TJ Biopharma Co., Ltd. | Healthy | 08/24 | 08/24 | | |
NCT06064929: A Study of Felzartamab in Participants With Lupus Nephritis |
|
|
| Recruiting | 1 | 20 | Canada, US, RoW | Felzartamab, HIB202 | HI-Bio | Lupus Nephritis | 06/26 | 06/26 | | |
| eftansomatropin alfa (GX-H9) / Genexine |
NCT04633057: A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency |
|
|
| Completed | 3 | 168 | RoW | TJ101, NordiFlex | TJ Biopharma Co., Ltd. | Pediatric Growth Hormone Deficiency | 07/23 | 07/23 | | |
| olamkicept (FE999301) / Ferring |
NCT06298032: A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons |
|
|
| Recruiting | 1 | 48 | Europe | Olamkicept Part A, FE 999301, Olamkicept Part B, Placebo | Ferring Pharmaceuticals | Inflammatory Gastrointestinal Diseases | 11/24 | 11/24 | | |
NCT06515834: Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons |
|
|
| Recruiting | 1 | 24 | Japan | FE 999301, Placebo | Ferring Pharmaceuticals | Gastroenterology | 11/24 | 11/24 | | |
| uliledlimab (TJD5) / I-Mab, Tracon Pharma |
NCT05001347: A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors |
|
|
| Completed | 2 | 25 | US | TJ004309 | I-Mab Biopharma US Limited | Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma | 02/23 | 02/23 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT03835949: Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer |
|
|
| Active, not recruiting | 1 | 36 | US | TJ004309, Atezolizumab | Tracon Pharmaceuticals Inc. | Solid Tumor, Metastatic Cancer | 06/22 | 06/22 | | |
|
NCT04869501: Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer |
|
|
| No Longer Available | N/A | | US | TJ004309, Atezolizumab, Tecentriq | I-Mab Biopharma US Limited | Cancer | | | | |
| Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech |
NCT04810637: A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19 |
|
|
| Recruiting | 2 | 210 | RoW | GX-I7, Efineptakin alfa NT-I7, rhIL-7-hyFc, NT-I7, TJ107 | PT Kalbe Genexine Biologics, Genexine, Inc. | Covid19 | 06/21 | 09/21 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT04600817: A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
|
|
| Active, not recruiting | 2 | 160 | RoW | TJ107, TJ107 placebo | TJ Biopharma Co., Ltd. | Newly Diagnosed Glioblastoma | 12/24 | 12/24 | | |
NCT04984811: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC |
|
|
| Active, not recruiting | 2 | 83 | US | efineptakin alfa, NT-I7, Atezolizumab, Tecentriq | NeoImmuneTech, Roche Pharma AG | Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer | 09/24 | 03/25 | | |
NCT05465954: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma |
|
|
| Recruiting | 2 | 44 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Efineptakin alfa, GX-I7, Hyleukin-7 (TM), Il-7 Hybrid Fc, IL-7-hyFc, NT-I7, rhIL-7-hyFc, TJ 107, TJ-107, TJ107, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Biopsy, BIOPSY_TYPE, Bx | Mayo Clinic, NeoImmune Tech, Merck Sharp & Dohme LLC | High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | 10/24 | 10/25 | | |
NCT05191784: GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients |
|
|
| Active, not recruiting | 2 | 20 | RoW | GX-I7, rhIL-7-hyFc, Efineptakin alfa, Bevacizumab, Avastin | Genexine, Inc. | Recurrent Glioblastoma | 12/24 | 12/24 | | |
GENUINE, NCT05286060: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer |
|
|
| Recruiting | 2 | 56 | RoW | GX-188E, GX-I7, Pembrolizumab, GX-188E, Pembrolizumab, GX-188E, GX-I7 | Yonsei University, Genexine, Inc., NeoImmuneTech | Head and Neck Squamous Cell Carcinoma | 08/25 | 12/25 | | |
TRINITY, NCT05280457: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy |
|
|
| Recruiting | 2 | 21 | RoW | nivolumab-GX-188E-GX-I7 | Yonsei University | Head and Neck Squamous Cell Carcinoma | 03/26 | 03/26 | | |
KEYNOTE-899, NCT03752723: Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/) |
|
|
| Completed | 1/2 | 84 | RoW | GX-I7, Efineptakin alfa, Pembrolizumab(KEYTRUDA®), KEYTRUDA®, MK-3745, Cyclophosphamide | Genexine, Inc., Merck Sharp & Dohme LLC | Triple Negative Breast Cancer | 05/23 | 05/23 | | |
NCT03901573: High-Risk Skin Cancers With Atezolizumab Plus NT-I7 |
|
|
| Terminated | 1/2 | 31 | US | NT-I7, efineptakin alfa, rhIL-7-hyFc, atezolizumab, Tecentriq | NeoImmuneTech, Immune Oncology Network | Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | 08/23 | 08/23 | | |
KEYNOTE A60, NCT04332653: NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 215 | US | NT-I7, Efineptakin alfa, rhIL-7-hyFc, pembrolizumab (KEYTRUDA®), KEYTRUDA® | NeoImmuneTech, Merck Sharp & Dohme LLC | Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer | 11/24 | 12/24 | | |
NCT05600920: A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia |
|
|
| Recruiting | 1/2 | 60 | US | Recombinant human interleukin (IL) 7-hyFc | National Institute of Allergy and Infectious Diseases (NIAID), NeoImmune Tech | Idiopathic CD4 Lymphopenia | 11/26 | 11/26 | | |
NCT03687957: rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide |
|
|
| Recruiting | 1/2 | 70 | US | rhIL-7-hyFc, Placebo, Temozolomide, TMZ, Radiation therapy, RT, Blood sample | Washington University School of Medicine, NeoImmuneTech, The Foundation for Barnes-Jewish Hospital | Glioma | 01/32 | 01/32 | | |
NCT04380948: A Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Enhance Immune Clearance of SARS-CoV-2 (COVID-19) |
|
|
| Not yet recruiting | 1 | 30 | US | NT-17, Placebo, Supportive care, Peripheral blood draw | Washington University School of Medicine | COVID-19, SARS-CoV-2 | 02/21 | 02/21 | | |
| Terminated | 1 | 7 | US | Double-Blind NT-I7, rhIL-7-hyFc, efineptakin alfa, Double-Blind Placebo | NeoImmuneTech, National Institute of Allergy and Infectious Diseases (NIAID), University of Nebraska | COVID-19 | 07/21 | 02/23 | | |
NCT04476290: A Double-Blind, Randomized, Placebo-Controlled, Phase 1, Single-Dose, Dose-Escalating Trial of Long-Acting Recombinant Human IL-7 (NT-I7) for COVID-19 |
|
|
| Recruiting | 1 | 60 | US | Recombinant human interleukin 7-hyFc, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | SARs CoV 2 | 12/21 | 12/21 | | |
NCT02659800: Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas |
|
|
| Terminated | 1 | 12 | US | Laboratory Biomarker Analysis, NT-I7, Placebo | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), NeoImmuneTech | Lymphopenia, Malignant Glioma | 03/22 | 10/23 | | |
NCT06344715: Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. |
|
|
| Recruiting | 1 | 78 | RoW | SL-T10, GX-I7, Pembrolizumab | SL VAXiGEN | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 10/24 | 10/24 | | |
| Terminated | 1 | 10 | Europe, US | NT-I7, Efineptakin alfa, rhIL-7-hyFc, Nivolumab | NeoImmuneTech, Bristol-Myers Squibb | Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) | 05/23 | 05/23 | | |
| Withdrawn | 1 | 68 | US | Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2 | National Cancer Institute (NCI), NeoImmuneTech | Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma | 11/23 | 11/23 | | |
NCT04893018: NT-I7 for Kaposi Sarcoma in Patients With or Without HIV |
|
|
| Terminated | 1 | 8 | US | Efineptakin alfa, 2026634-47-7, GX-I7, Hyleukin-7 (TM), Il-7 Hybrid Fc, IL-7-hyFc, NT-I7, rhIL-7-hyFc | Fred Hutchinson Cancer Center, Cancer Immunotherapy Trials Network (CITN), National Cancer Institute (NCI) | AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma | 12/23 | 12/23 | | |
NCT04588038: NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery |
|
|
| Recruiting | 1 | 10 | US | Efineptakin alfa, GX-I7, Hyleukin-7 (TM), Il-7 Hybrid Fc, IL-7-hyFc, NT-I7, rhIL-7-hyFc, TJ 107, TJ-107, TJ107 | Hyunseok Kang, MD, NeoImmuneTech | Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Resectable Oropharyngeal Squamous Cell Carcinoma | 03/25 | 03/25 | | |
NCT05075603: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy |
|
|
| Recruiting | 1 | 57 | US | Efineptakin alfa, NT-I7, rhIL-7-hyFc, Tisagenlecleucel, Kymriah, Axicabtagene ciloleucel, Yescarta, Lisocabtagene Maraleucel, Breyanzi | NeoImmuneTech | Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 11/24 | 02/26 | | |
NCT04781309: NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy |
|
|
| Recruiting | 1 | 12 | US | NT-I7 | National Institute of Neurological Disorders and Stroke (NINDS), NeoImmuneTech | Progressive Multifocal Leukoencephalopathy | 01/26 | 01/26 | | |
| No Longer Available | N/A | | RoW | GX-I7 | Genexine, Inc. | Glioblastoma, High Grade Glioma, Recurrent Glioblastoma, Melanoma, Advanced Cancer | | | | |
| GX-G6 / Genexine |
| Not yet recruiting | 3 | 300 | NA | TG103, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 03/26 | 11/26 | | |
NCT06235086: Phase 3 Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 618 | RoW | TG103, Dulaglutide | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 03/26 | 11/26 | | |
NCT05997576: A Study of TG103 Injection in Non-diabetic Overweight or Obesity |
|
|
| Not yet recruiting | 3 | 675 | RoW | TG103 22.5 mg, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Overweight or Obesity | 01/25 | 04/25 | | |
ChiCTR2100051312: A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 2 | 186 | | TG103 (15 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes combined with overweight/obesity. ;TG103 (22.5 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes combined with overweight/obesity. ;TG103 (30 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes combined with overweight/obesity. ;Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes will be administered via subcutaneous injection once weekly. | Nanjing Drum Tower Hospital Affiliated to Medical College of Nanjing University; Nanjing Drum Tower Hospital Affiliated to Medical College of Nanjing University, CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes | | | | |
NCT05299697: A Study of TG103 Injection in Overweight or Obesity |
|
|
| Recruiting | 2 | 195 | RoW | TG103 15 mg, TG103 22.5 mg, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Overweight or Obesity | 06/23 | 09/23 | | |
NCT05348122: A Study of TG103 Injection in Type 2 Diabetes Subjects |
|
|
| Not yet recruiting | 2 | 240 | RoW | TG103,Q2W, TG103 injection, subcutaneous injection,Q2W, TG103,QW, TG103 injection, subcutaneous injection,QW, Placebo,Q2W, Placebo, subcutaneous injection,Q2W, Placebo,QW, Placebo, subcutaneous injection,QW, Dulaglutide,QW, Dulaglutide,subcutaneous injection,QW | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 11/23 | 11/23 | | |
NCT06226090: A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity |
|
|
| Active, not recruiting | 2 | 300 | RoW | TG103 7.5 mg, Placebo 7.5 mg, TG103 15 mg, Placebo 15 mg, TG103 22.5 mg, Placebo 22.5 mg | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Obesity, Overweight | 12/24 | 03/25 | | |
NCT05063253: A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 2 | 208 | NA | TG103, Administered SC, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 03/24 | 03/24 | | |
NCT04790006: A Study of TG103 in Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 1 | 54 | NA | TG103, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Type 2 Diabetes | 03/22 | 03/22 | | |
NCT04855292: A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes |
|
|
| Completed | 1 | 48 | RoW | TG103 injection, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Diabetes | 12/22 | 01/23 | | |
| lemzoparlimab (ABBV-IMAB-TJC4) / I-Mab |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
| Completed | 1 | 98 | US, RoW | TJ011133, Pembrolizumab, KEYTRUDA®, Rituximab, Rituxan, MabThera | I-Mab Biopharma US Limited, Merck Sharp & Dohme LLC | Solid Tumor, Lymphoma | 01/23 | 01/23 | | |
NCT04912063: Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome |
|
|
| Terminated | 1 | 40 | Europe, Japan, US, RoW | Lemzoparlimab, TJ011133, ABBV-IMAB-TJC4, Azacitidine, Venetoclax, Venclexta, Venclyxto, ABT-199, GDC-0199 | AbbVie | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 05/23 | 05/23 | | |
| plonmarlimab (TJM2) / I-Mab |
NCT04457856: A Study of TJ003234 in Rheumatoid Arthritis Patients |
|
|
| Recruiting | 1 | 63 | RoW | TJ003234 injection | I-Mab Biopharma Co. Ltd. | Rheumatoid Arthritis | 03/23 | 03/23 | | |
| izastobart (HIB210) / Biogen |
NCT05928585: A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers |
|
|
| Completed | 1 | 30 | US | HIB210, Placebo | HI-Bio | Immune System Diseases, Autoimmunity | 06/24 | 06/24 | | |
NCT04947033: A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 25 | RoW | TJ210001 Injection | I-Mab Biopharma Co. Ltd. | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT05511350: Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001 |
|
|
| No Longer Available | N/A | | NA | TJ210001 | I-Mab Biopharma Co. Ltd. | Solid Tumor Metastatic Cancer Advanced Cancer | | | | |
| givastomig (TJ-CD4B) / I-Mab, ABL Bio |
NCT04900818: Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 168 | US, RoW | TJ033721, TJ033721, nivolumab, chemotherapy | I-Mab Biopharma US Limited | Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma | 12/24 | 12/25 | | |
| ragistomig (ABL503) / ABL Bio, I-Mab |
ABL503-1001, NCT04762641: This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 100 | US, RoW | ABL503 | ABL Bio, Inc. | Advanced Solid Tumor | 06/25 | 06/25 | | |
| TJ-L1I7 / I-Mab |
| No trials found |
| TJ-C4GM / I-Mab |
| No trials found |
| Protollin / I-Mab |
| No trials found |
| TJ-C64B / I-Mab |
| No trials found |
| TJA3 / I-Mab |
| No trials found |
| TJ-L1IF / I-Mab |
| No trials found |
